NCT01327768

Brief Summary

Recruited patients should receive the endoscopic surgery for picking the olfactory mucosa 1 to 2 months before transplantation. The Olfactory Ensheathing Cells (OECs) will be cultured and expanded under the rule of GTP. Then, quality control of OECs should be done by immunohistochemical staining positive for GFAP, S100, and P75. Finally, the investigators will transplant the OECs (about 2 to 8 X 10´6 cells in saline) into the peri-infarcted area of the brain.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
6

participants targeted

Target at below P25 for phase_1

Timeline
Completed

Started Jan 2011

Typical duration for phase_1

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2011

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

January 31, 2011

Completed
2 months until next milestone

First Posted

Study publicly available on registry

April 4, 2011

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2013

Completed
Last Updated

October 3, 2011

Status Verified

September 1, 2011

Enrollment Period

2.3 years

First QC Date

January 31, 2011

Last Update Submit

September 29, 2011

Conditions

Keywords

Stroke,Stem Cell,Olfactory Ensheathing Cells,Intracerebral Implantation of Olfactory Ensheathing Cells.

Outcome Measures

Primary Outcomes (1)

  • NIH-Stroke Scale

    National Institute of Health-Stroke Scale will be performed to evaluate including muscle power of hemiparetic limbs, sensory function and flurency of speech of each patient to document the therapeutic effect.

    within 1 year after surgery

Secondary Outcomes (2)

  • MRI(DTI)

    within 1 year after surgery

  • TMS(MEP)

    within 1 year after surgery

Study Arms (1)

OECs, Medicine, Rehabilitation

EXPERIMENTAL

Stroke patients are received intracerebral implantation of Olfactory ensheathing cells(OECs), Antiplatelet Medication, and Rehabilitation.

Procedure: Olfactory ensheathing cells

Interventions

Recruited patients should be received the endoscopic surgery for picking the olfactory mucosa 1 to 2 months before transplantation. The OECs will be cultured and expanded under the rule of GTP. Finally, we will transplant the OECs (about 2 to 8 X 10´6 cells in saline) into the peri-infarcted area of the brain for old stroke ischemic patients.

Also known as: Stroke,, Stem Cells,, Olfactory Ensheathing Cells,, Early Phase Clinical Trial.
OECs, Medicine, Rehabilitation

Eligibility Criteria

Age35 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Aged 35-70 year old Chronic Stroke Adult Patients,
  • With Stroke History of More Than 6 Months, Less Than 60 Months,
  • With Stable Hemiplegia Condition,
  • NIHSS Score Is Between 5\~15.

You may not qualify if:

  • Patients Aged Less Than 35 or More Than 70,
  • Hemorrhage Stroke or MRI Show The Occlusion Is Not In The Middle Cerebral Artery Territory,
  • NIHSS Is Not In The Range of 5\~15,
  • Pregnant Women,
  • Impaired Liver Function, Abnormal Blood Coagulation, AIDS Carrier, Tumors, Other Special Conditions, etc.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

China Medical University Hospital, Center of Neuropsychiatry

Taichung, 40447, Taiwan

RECRUITING

MeSH Terms

Conditions

Infarction, Middle Cerebral ArteryIschemic StrokeStroke

Condition Hierarchy (Ancestors)

Cerebral InfarctionBrain InfarctionBrain IschemiaCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesCerebral Arterial DiseasesIntracranial Arterial DiseasesVascular DiseasesCardiovascular DiseasesInfarctionIschemiaPathologic ProcessesPathological Conditions, Signs and SymptomsNecrosis

Study Officials

  • Woei-Cherng Shyu, M.D., Ph.D

    shyu9423@gmail.com

    STUDY CHAIR

Central Study Contacts

Hsiao-Jung Wang, M.S.

CONTACT

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 31, 2011

First Posted

April 4, 2011

Study Start

January 1, 2011

Primary Completion

May 1, 2013

Study Completion

May 1, 2013

Last Updated

October 3, 2011

Record last verified: 2011-09

Locations